Annals of Oncology 8:555-559, 1997
© 1997 European Society for Medical Oncology
research-article |
Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy
Divisions of Medical Oncology Barcelona, Spain
1Hospital Universitario ‘12 de Octubre’ Madrid, Spain
2Hospital Universitario ‘Marqués de Valdecilla’ Santander, Spain
3Hospital Universitario de Sant Pau Barcelona, Spain
Correspondence to: Luis Paz-Ares, MD, PhD Servicio de Oncologia Médica Hospital Univ ‘12 de Octubre’ Avd Córdoba Km 5.4. 28041 Madrid Spain
BACKGROUND: Primary mediastinal non-seminomatous germ cell tumours (MNSGCT) constitute a rare malignancy. This study was performed to review our experience with cispatin-based chemotherapy in patients with MNSGCT.
PATIENTS AND METHODS: Patients with MNSGCT treated with cisplatin-based combination chemotherapy between 1978–1995 in three university hospitals in Spain were retrospectively studied.
RESULTS: There were 25 males and two females with a median age of 26 years (range 4–71). Fifteen patients had disease confined to the mediastinum and 12 had metastatic disease. All patients were treated with cisplatin chemotherapy regimens (PVB: 7, BEP: 6, and other regimens 12) and considered for residual mass surgery (RMS) when indicated. Eleven patients (40.7%) were rendered disease-free with initial treatment: four with chemotherapy alone, one with surgery plus adjuvant chemotherapy and six with chemotherapy plus RMS. Three of these patients relapsed at two, six and seven months. The remaining 16 had unfavourable reponses (five partial response, three no change, seven progressive disease and one toxic death) . Eleven patients received salvage treatment but none of them achieved a durable response. After a median follow-up of 77 months (range 1–168), 10 patients remain alive. Actuarial survival at five years is 31.7%. No patients in this series developed a haematological malignancy. Chromosomal analysis showed that 2 out of 10 patients (20%) had a 47XXY karyotype.
CONCLUSIONS: Only patients who achieved disease-free status are likely to be cured. Therefore, new up-front strategies are needed for the treatment of MNSGCT.
germ cell tumours, extragonadal, mediastinum, cisplatin-based chemotherapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Radaideh, V. C. Cook, K. A. Kesler, and L. H. Einhorn Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy Ann. Onc., November 4, 2009; (2009) mdp516v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Kesler, K. M. Rieger, Z. T. Hammoud, L. E. Kruter, S. M. Perkins, M. W. Turrentine, B. P. Schneider, L. H. Einhorn, and J. W. Brown A 25-Year Single Institution Experience With Surgery for Primary Mediastinal Nonseminomatous Germ Cell Tumors Ann. Thorac. Surg., February 1, 2008; 85(2): 371 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Schneider, K. A. Kesler, J. A. Brooks, C. Yiannoutsos, and L. H. Einhorn Outcome of Patients With Residual Germ Cell or Non-Germ Cell Malignancy After Resection of Primary Mediastinal Nonseminomatous Germ Cell Cancer J. Clin. Oncol., April 1, 2004; 22(7): 1195 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bokemeyer, C. R. Nichols, J.-P. Droz, H.-J. Schmoll, A. Horwich, A. Gerl, S. D. Fossa, J. Beyer, J. Pont, L. Kanz, et al. Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis J. Clin. Oncol., April 1, 2002; 20(7): 1864 - 1873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Kesler, K. M. Rieger, K. N. Ganjoo, M. Sharma, N. S. Fineberg, L. H. Einhorn, and J. W. Brown PRIMARY MEDIASTINAL NONSEMINOMATOUS GERM CELL TUMORS: THE INFLUENCE OF POSTCHEMOTHERAPY PATHOLOGY ON LONG-TERM SURVIVAL AFTER SURGERY J. Thorac. Cardiovasc. Surg., October 1, 1999; 118(4): 692 - 701. [Abstract] [Full Text] [PDF]
|
|